title: Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.
abstract: OBJECTIVE
  Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.
  
  
  METHODS
  We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.
  
  
  RESULTS
  After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.
  
  
  CONCLUSIONS
  Our results indicate that IFX is efficacious and safe for AS in Japanese patients.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kubo
authors.forename: Masanobu
authors.initials: M
authors.lastname: Ohishi
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Nakashima
authors.forename: Ken
authors.initials: K
authors.lastname: Okazaki
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Fukushi
authors.forename: Akiko
authors.initials: A
authors.lastname: Oyamada
authors.forename: Yukihide
authors.initials: Y
authors.lastname: Iwamoto
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D000069285:Infliximab